Evaluation of Serial Lung Ultrasound Data After Surfactant Treatments Applied With Different Methods in Preterm Babies

Launched by KONYA CITY HOSPITAL · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how different methods of delivering a treatment called surfactant can affect the lungs of preterm babies who have breathing problems, specifically those diagnosed with Respiratory Distress Syndrome (RDS). Surfactant is a substance that helps keep the lungs open and functioning properly. The researchers will use lung ultrasound, a special imaging technique, to see how well the babies’ lungs respond to the treatment over time.

To participate in this study, infants must be born before 32 weeks of pregnancy and need surfactant therapy for RDS. Families who agree to take part in the trial will help researchers understand which delivery method works best for improving the babies’ lung health. It's important to note that infants with certain conditions, such as congenital heart disease or specific genetic syndromes, are not eligible for the study. Overall, this trial aims to improve the care and outcomes for preterm infants with lung issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants of families who agree to participate in the study
• • Preterm infants born before 32 weeks of gestation requiring surfactant therapy due to an RDS diagnosis.
• Exclusion Criteria:
• • Infants whose families did not provide consent
• • Infants with a syndromic appearance or congenital heart disease
• • Preterm infants born after 32 weeks of gestation